Eplontersen · Wainua

RNA / oligonucleotide

Approvedregulatory verdict

Evidence outlook

Approved: Transthyretin Amyloidosis with Polyneuropathy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Weak signal

Also in development:Transthyretin Amyloidosis with Cardiomyopathy · Phase 3 · investigational in the US

Also approved (1)
EU
  • Treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adult patients with stage 1 or stage 2 polyneuropathy.
Product first approved 2025EMA
Featured evidence outside this drug's tracked markets:NCT04302064 · Healthy Participants · Phase 1 · completed · ungraded

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (5)
Transthyretin Amyloidosis with Cardiomyopathy
NCT05667493 · Ionis Pharmaceuticals, Inc.
2022-11-30 – 2029-08 · Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
What this study did
NCT06194825 · AstraZeneca
2023-12-01 – 2027-01-05 · Transthyretin Amyloid Cardiomyopathy
What this study did
Other / comorbidity
NCT05071300 · Ionis Pharmaceuticals, Inc.
2022-01-04 – 2029-08 · Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
What this study did
Phase 1/2 (1)
Phase 1 (2)
Other / comorbidity
NCT06527755 · AstraZeneca
2024-08-06 – 2024-11-15 · Transthyretin-mediated Amyloidosis
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Transthyretin Amyloidosis with Cardiomyopathy
NCT07608354 · AstraZeneca
2026-06-11 – 2029-02-06 · Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
What this study did

Competitive landscape

This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Transthyretin Amyloidosis with Polyneuropathy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Eplontersen (Wainua): this drugApprovedRNA / oligonucleotideTransthyretin (TTR)Weak signalNo reviewed efficacy summary in this indication
Patisiran (ONPATTRO)ApprovedRNA / oligonucleotideTransthyretin (TTR)Reliable signal
NCT01960348: Modified Neuropathy Impairment Score +7 (mNIS+7) (18mo): Patisiran (ALN-TTR02) -6.03 score on a scale (Standard Error 1.739) | Placebo 27.96 score on a scale (Standard Error 2.602)
Vutrisiran (AMVUTTRA)ApprovedRNA / oligonucleotideTransthyretin (TTR)Partial signal
NCT03759379: Change From Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 9 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)] (Baseline, Month 9): External Placebo Comparator (APOLLO) 14.76 score on a scale (Standard Error 2) | Vutrisiran + Vutrisiran (HELIOS-A) -2.24 score on a scale (Standard Error 1.43)
Inotersen (Tegsedi)US approval withdrawnRNA / oligonucleotideTransthyretin (TTR)Reliable signalNo reviewed efficacy summary in this indication
Coramitug
Phase 3(overall)
Monoclonal antibodyTransthyretin (TTR)
not yet graded(overall)
No reviewed efficacy summary in this indication
NucresiranPhase 3RNA / oligonucleotideTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Wainua (Eplontersen) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (2)
August 2029 (2)
Phase 3Hereditary Transthyretin-Mediated Amyloid PolyneuropathyActive not recruiting
Est. primary completion 2029-08 · NCT05071300 · CT.gov ↗
What to watch
Phase 3Transthyretin Amyloidosis with CardiomyopathyEnrolling by invitation
Est. primary completion 2029-08 · NCT05667493 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

July 2026Topline resultPhase 3 CARDIO-TTRansform missed its primary endpoint